Thermal liquid biopsy (TLB) focused on benign and premalignant pancreatic cyst diagnosis

Hermoso-Durán, S. ; García-Rayado, G. ; Ceballos-Laita, L. ; Sostres, C. (Universidad de Zaragoza) ; Vega, S. ; Millastre, J. ; Sánchez-Gracia, O. ; Ojeda, J.L. (Universidad de Zaragoza) ; Lanas, Á. (Universidad de Zaragoza) ; Velázquez-Campoy, A. (Universidad de Zaragoza) ; Abian, O. (Universidad de Zaragoza)

Resumen: Background: Current efforts in the identification of new biomarkers are directed towards an accurate differentiation between benign and premalignant cysts. Thermal Liquid Biopsy (TLB) has been previously applied to inflammatory and tumor diseases and could offer an interesting point of view in this type of pathology.
Methods: In this work, twenty patients (12 males and 8 females, average ages 62) diagnosed with a pancreatic cyst benign (10) and premalignant (10) cyst lesions were recruited, and biological samples were obtained during the endoscopic ultrasonography procedure.
Results: Proteomic content of cyst liquid samples was studied and several common proteins in the different groups were identified. TLB cyst liquid profiles reflected protein content. Also, TLB serum score was able to discriminate between healthy and cysts patients (71% sensitivity and 98% specificity) and between benign and premalignant cysts (75% sensitivity and 67% specificity).
Conclusions: TLB analysis of plasmatic serum sample, a quick, simple and non-invasive technique that can be easily implemented, reports valuable information on the observed pancreatic lesion. These preliminary results set the basis for a larger study to refine TLB serum score and move closer to the clinical application of TLB providing useful information to the gastroenterologist during patient diagnosis.

Idioma: Inglés

DOI: 10.3390/jpm11010025

Año: 2021

Publicado en: Journal of Personalized Medicine 11, 1 (2021), 25 [19 pp]
ISSN: 2075-4426

Factor impacto JCR: 3.508 (2021)

Categ. JCR: MEDICINE, GENERAL & INTERNAL rank: 69 / 172 = 0.401 (2021) - Q2 - T2
Categ. JCR: HEALTH CARE SCIENCES & SERVICES rank: 42 / 109 = 0.385 (2021) - Q2 - T2

Factor impacto CITESCORE: 1.8 - Medicine (Q3)

Factor impacto SCIMAGO: 0.757 - Medicine (miscellaneous) (Q2)

Financiación: info:eu-repo/grantAgreement/ES/DGA/E45-17R
Financiación: info:eu-repo/grantAgreement/ES/FIS/PI15-00663
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/CIBERehd
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/CPII13-00017
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-ESF/Investing in your future
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-FIS/FI19-00146
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-FIS/PI18-00349
Financiación: info:eu-repo/grantAgreement/ES/MCIU-AEI-FEDER/BFU2016-78232-P

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Estadís. Investig. Opera. (Dpto. Métodos Estadísticos)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)